^
Association details:
| Biomarker: | IDH2 mutation |
|---|---|
| Cancer: | Hematological Malignancies |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Idhifa (enasidenib) (IDH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
159 Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2-Mutated Relapsed/Refractory Myeloid Malignancies
Published date:
11/02/2023
Excerpt:
The median OS was 9.4 months (95% CI, 8.2 – NR) and the 2-year OS rate was 42% (95% CI, 27 – 66). Four pts proceeded to HSCT after achieving remission, of whom 2/4 (50%) are alive in remission on last follow-up….The combination of ENA and VEN is safe and well tolerated in pts with R/R mIDH2 myeloid malignancies. The ENA-VEN combination compares favorably to ENA single-agent in this patient population.
Trial ID:
